The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole

Simple item page
dc.contributor.authorCarlos Robello
dc.contributor.authorDoris Patricia Maldonado
dc.contributor.authorAnna Hevia
dc.contributor.authorMarina Hoashi
dc.contributor.authorPaola Frattaroli
dc.contributor.authorValentina Montacutti
dc.contributor.authorAdriana Heguy
dc.contributor.authorIgor Dolgalev
dc.contributor.authorMaricruz Mojica
dc.contributor.authorGregorio Iraola
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:12:44Z
dc.date.available2026-03-22T14:12:44Z
dc.date.issued2019
dc.descriptionCitaciones: 30
dc.description.abstractThe results of this study show differences in the fecal microbiota associated with Chagas disease in children, and also evidence that treatment normalizes fecal microbiota (makes it more similar to that in controls), but is associated with oral and skin microbiota differences from control children. Since microbiota impacts in children, it is important to determine the effect of drugs on the children microbiota, since dysbiosis could lead to physiological effects which might be avoidable with microbiota restoration interventions.
dc.identifier.doi10.1371/journal.pone.0212593
dc.identifier.urihttps://doi.org/10.1371/journal.pone.0212593
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45190
dc.language.isoen
dc.publisherPublic Library of Science
dc.relation.ispartofPLoS ONE
dc.sourceInstitut Pasteur de Montevideo
dc.subjectBenznidazole
dc.subjectChagas disease
dc.subjectFeces
dc.subjectPrevotella
dc.subjectBiology
dc.subjectTrypanosoma cruzi
dc.subjectBacteroides
dc.subjectMicrobiome
dc.subjectMedicine
dc.subjectImmunology
dc.titleThe fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
dc.typearticle

Files

Collections

Artículo Científico Publicado